Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.30 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.30 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.30 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29862003 | 1.00 | ALDH1A1 (0.37) | ALDH1A1SOS1FAAHCA1CA2 | |
| SCHEMBL6314176 | 0.79 | GABRA1 (0.46) | ALDH1A1FAAHCA1CA2LMNA | |
| SCHEMBL6891458 | 0.79 | ALDH1A1 (0.39) | ALDH1A1FAAHCA1CA2LMNA | |
| SCHEMBL30657429 | 0.79 | GABRA1 (0.46) | ALDH1A1FAAHCA1CA2LMNA | |
| SCHEMBL17369378 | 0.79 | — | — | |
| SCHEMBL16955883 | 0.76 | ADRA2A (0.43) | ALDH1A1FAAHCA1CA2LMNA | |
| SCHEMBL23526278 | 0.76 | CYP3A4 (0.45) | ALDH1A1FAAHCA1CA2LMNA | |
| SCHEMBL16962051 | 0.76 | ALDH1A1 (0.36) | ALDH1A1SOS1FAAHCA1CA2 | |
| SCHEMBL30014285 | 0.76 | CYP3A4 (0.45) | ALDH1A1FAAHCA1CA2LMNA | |
| SCHEMBL15320312 | 0.76 | CYP3A4 (0.45) | ALDH1A1FAAHCA1CA2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4620531-A2 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | Revolution Medicines, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| US-20250230147-A1 | LACTAMS AS CBL-B INHIBITORS | GENENTECH, INC. (US) | 2025-07-17 | — | — | US | disclosed |
| US-12258366-B2 | Bicyclic heteroaryl compounds and uses thereof | Revolution Medicines, Inc. (US) | 2025-03-25 | — | — | US | disclosed |
| CN-117580836-A | Pyrimidine ring structure derivative and application thereof | 四川汇宇制药股份有限公司 | 2024-02-20 | — | — | CN | disclosed |
| EP-4288429-A1 | LACTAMS AS CBL-B INHIBITORS | Genentech, Inc. (US) | 2023-12-13 | — | — | EP | disclosed |
| US-20230365605-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-11-16 | — | — | US | disclosed |
| US-20230365605-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-11-16 | — | — | US | disclosed |
| US-11814380-B2 | Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-11-14 | — | — | US | disclosed |
| US-11814380-B2 | Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-11-14 | — | — | US | disclosed |
| CN-116888112-A | Lactams as CBL-B inhibitors | 基因泰克公司 | 2023-10-13 | — | — | CN | disclosed |
| US-20220324862-A1 | PYRIDOPYRIMIDINONE COMPOUNDS | ACERAND THERAPEUTICS (USA) LIMITED | 2022-10-13 | — | — | US | disclosed |
| EP-4055017-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | Revolution Medicines, Inc. (US) | 2022-09-14 | — | — | EP | disclosed |
| CN-114901662-A | Bicyclic heteroaryl compounds and uses thereof | 锐新医药公司 | 2022-08-12 | — | — | CN | disclosed |
| WO-2022169997-A1 | LACTAMS AS CBL-B INHIBITORS | GENENTECH, INC. (US) | 2022-08-11 | — | — | WO | disclosed |
| US-11168102-B1 | Bicyclic heteroaryl compounds and uses thereof | Revolution Medicines, Inc. (US) | 2021-11-09 | — | — | US | disclosed |
| US-20210139517-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | Revolution Medicines, Inc. | 2021-05-13 | — | — | US | disclosed |
| US-20210009588-A1 | NOVEL BENZYLAMINO SUBSTITUTED PYRIDOPYRIMIDINONES AND DERIVATIVES AS SOS1 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2021-01-14 | — | — | US | disclosed |
| WO-2020254451-A1 | ANTICANCER COMBINATION THERAPY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-12-24 | — | — | WO | disclosed |
| US-10829487-B2 | Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-11-10 | — | — | US | disclosed |
| US-20190194192-A1 | NOVEL BENZYLAMINO SUBSTITUTED PYRIDOPYRIMIDINONES AND DERIVATIVES AS SOS1 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009588-A1 | NOVEL BENZYLAMINO SUBSTITUTED PYRIDOPYRIMIDINONES AND DERIVATIVES AS SOS1 INHIBITORS | SOS1, SOST, SOS2 | ALDH1A1 1453/4885SOS1 1/4885FAAH 4727/4885 |
| US-20250230147-A1 | LACTAMS AS CBL-B INHIBITORS | CBLB, CBL, CBLC | ALDH1A1 4354/4885SOS1 165/4885FAAH 3907/4885 |
| US-11168102-B1 | Bicyclic heteroaryl compounds and uses thereof | SOS1, SOST, SOS2 | ALDH1A1 3199/4885SOS1 1/4885FAAH 4389/4885 |
| US-20230365605-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | SOST, SOS1, SOS2 | ALDH1A1 3594/4885SOS1 2/4885FAAH 4022/4885 |
| US-11814380-B2 | Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors | SOS1, SOST, BMP1 | ALDH1A1 1272/4885SOS1 1/4885FAAH 4809/4885 |
| US-20190194192-A1 | NOVEL BENZYLAMINO SUBSTITUTED PYRIDOPYRIMIDINONES AND DERIVATIVES AS SOS1 INHIBITORS | SOS1, SOST, SOS2 | ALDH1A1 1511/4885SOS1 1/4885FAAH 4739/4885 |
| US-20210139517-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | SOST, SOS1, SOS2 | ALDH1A1 3594/4885SOS1 2/4885FAAH 4022/4885 |
| US-10829487-B2 | Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors | SOS1, SOST, BMP1 | ALDH1A1 1301/4885SOS1 1/4885FAAH 4815/4885 |
| US-20220324862-A1 | PYRIDOPYRIMIDINONE COMPOUNDS | RSU1, SOST, CCNA1 | ALDH1A1 1616/4885SOS1 9/4885FAAH 4836/4885 |
| US-12258366-B2 | Bicyclic heteroaryl compounds and uses thereof | SOST, SOS1, SOS2 | ALDH1A1 3594/4885SOS1 2/4885FAAH 4022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.